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Abstract
Background: In Central and South America and Eastern and Southern Africa, Plasmodium vivax infections accounts
for 71-81% and 5% of malaria cases, respectively. In these areas, chloroquine (CQ) remains the treatment of choice
for P. vivax malaria. In addition, CQ has recently proven to be an effective HIV-1 therapeutic agent. There is a dire
need to continue monitoring quality of CQ as there is a major influx of substandard and fake formulations into
malaria-endemic countries. The use of fake/substandard drugs will result in sub-therapeutic levels endangering the
patient and possibly select for parasite resistance. The aim of this study was to develop an inexpensive, simple
antibody-based ELISA to measure CQ concentrations in tablets and in plasma.
Methods: A monoclonal antibody (MAb) that reacts with the N-side chain of the CQ molecule was prepared by
use of a CQ analogue. A specific and reliable ELISA for detection of CQ was developed. The developed assay was
validated by measuring CQ in tablets sold in Denmark, India and Sudan. Furthermore, kinetics of CQ concentrations
in plasma of four volunteers, who ingested two tablets of Malarex® containing, 250 mg CQ base, were measured
before drug intake, three hours later and thereafter at days 1, 3, 7, 14, 21 and 28. The same plasma samples were
simultaneously measured by high performance liquid chromatography (HPLC).
Results: The ELISA proved an easy-to-handle and very sensitive tool for the detection of CQ with a lower limit of
detection at 3.9 ng/ml. ELISA levels of CQ in plasma showed high agreement with the levels obtained by HPLC
(r = 0.98). The specificity in the negative control group was 100%.
Conclusion: The developed ELISA can be used for quality screening of CQ in pharmaceutical formulations and for
drug monitoring in malaria and in other infectious diseases, such as HIV, where CQ proved to be an effective
therapeutic agent. The methodology has been exploited to develop monoclonal antibodies for the drugs used in
artemisinin-based combination therapy (ACT).
Background
Malaria-associated morbidity and mortality both in chil-
dren and adults is reported in many tropical countries.
Plasmodium vivax accounts for over half of all malaria
transmitted outside Africa. The development and spread
of drug resistance in malaria parasites has spurred on a
global change in policy from the use of the former first-
line anti-malarials chloroquine (CQ) and sulphadoxine/
pyrimethamine (SP) to the use of artemisinin-based
combination therapy (ACT) for uncomplicated malaria.
However, CQ is still the first-line treatment for P. vivax
malaria in most parts of the world [1-3].
Ensuring that the ACT reaches the majority of chil-
dren and vulnerable adults in need has proved challen-
ging and the reality on the ground is a continued use of
CQ and SP in private and public facilities [4]. CQ con-
tinues to be widely used in Madagascar, despite having
been officially replaced by ACT for treatment of uncom-
plicated falciparum malaria in 2005 [5]. Prepackaged CQ
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is still recommended by the Ministry of Health and
Family Planning for the home management of presumed
malaria in children under the age of five years [5].
Marketing of fake/substandard CQ has been widely
reported in malaria endemic areas with a weak drug reg-
ulatory system [6-10]. The intake of fake medicines can
have life-threatening consequences, such as patients suf-
fering or death and numerous adverse effects due to
ineffectiveness, under-dosing, over-dosing, unexpected
or toxic substances [6,8]. Moreover, it will influence the
economic welfare of patients as treatment has to be
repeated several times and consequently patients will
lose trust in health systems [6]. Finally, use of substan-
dard CQ will most
likely increase risk of selection and spreading of drug
resistance to the structurally and/or functionally related
ACT partners currently in use, including amodiaquine
[8,9].
Thus, there is an urgent need to invest in develop-
ing simple, quick, inexpensive and sensitive methods
to measure levels of active drugs in pharmaceutical
formulations at point-of-purchase and in patient ’s
plasma in clinical trials that monitor susceptibility of
P. vivax to CQ. Current methods for quantification of
CQ in plasma and in pharmaceutical formulations
include fluorimetry, gas liquid chromatography, high
performance liquid chromatography (HPLC) and
radio-immunoassays [11-14]. Even though the chro-
matographic methods offer the required sensitivity,
reliability and specificity, they require expensive and
complex equipment as well as highly trained staff.
Their use is thus restricted to well-equipped labora-
tories, which may often not be accessible in malaria-
endemic areas.
ELISA assays using poly or monoclonal antibodies
(MAb) against CQ have been developed, but with low
specificity for CQ as they recognize all compounds bear-
ing the 4-aminoquinoline moiety, in particular CQ’s
main metabolite, desethyl CQ, amodiaquine and its
metabolite desethyl amodiaquine because the antibodies
have been raised against the quinoline group [15-18]. A
specific ELISA has been developed for detection of CQ
in urine and blood spotted on filter paper by raising
polyclonal antibodies in sheep against CQ conjugated to
keyhole limpet haemocyanin immunogen [19].
The aim of this study was to develop field applicable
ELISA methods for estimating CQ levels in clinical spe-
cimens and in tablets through the production of high-
affinity monoclonal antibody against the N-side chain of
CQ. The monoclonal antibody was developed in colla-
boration with University of Southern Denmark and the
private company Bio Port A/S, Denmark. The procedure
resulted in a monoclonal antibody designated HYB 317-
01. The antibody is commercially available.
Methods
CQ (purity 98%), 2-amino-5-diethylaminopentane (ADP)
and bovine serum albumin (BSA) were provided by
Sigma-Aldrich (Denmark). The carrier protein, S3
(secreted proteins from cultures of Bacillus-Calmette-
Guerin) and Bacillus-Calmette-Guerin (BCG) vaccines
were kindly provided by The State Serum Institute
(Denmark). Polyclonal anti-mouse immunoglobins/HRP
P0260 antibody and OPD were purchased from Dako
(Denmark). All other chemicals were standard commer-
cial products of analytical grade.
Development of the monoclonal antibody
Preparation of the conjugate
The hapten 2-amino-5-diethylaminopentane (ADP)
which corresponds to the N-side-chain of the 4-
amino-7-chloro-quinoline moiety of the CQ molecule
(Figure 1) was used for coupling to the immunogenic
carrier protein S3. A five-fold molar excess of ADP
was reacted with the protein using a standard glutaral-
dehyde coupling procedure [20].
Immunization and hybridization
Mouse experiments have been performed according to
permission 561-1758 from the Danish Animal Experi-
ments Inspectorate. Three months old female
CF1xBALB/c mice were pre-immunized with 0.2 ml
BCG vaccine 4 weeks prior to administration of the
ADP-S3. ADP-S3 was adsorbed onto Alhydrogel (Brenn-
tag Bio-sector, DK). Immunization doses of 25 μg ADP-
S3 containing 1 mg Al(OH)3 were given i.p. four times
with two week intervals (Claus Koch, personal commu-
nication). Boost vaccination before fusion was done i.v
with 25 μg ADP-S3.
 
 
Chloroquine    
 
 
 
2-amino-5-diethylaminopentane (ADP)
Figure 1 The chemical structure of chloroquine and the 2-
amino-5-diethylaminopentane (ADP).
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Three days after the i.v boosting, spleens were
removed from two mice with high titres of antibodies to
CQ, and the spleen cells were pooled and mixed with
myeloma cell line X63Ag8.653. Hybridoma cell lines
were prepared by fusing the cells using PEG [20]. The
fused cells were cultured in enriched RPMI 1640-Dul-
becco’s-Ham F12 medium containing an aminopterin to
selectively obtain hybridomas. The hybridoma culture
supernatants were screened by an ELISA in which ADP-
ovalbumin was used as solid phase antigen after cell
fusion. Furthermore, a competitive ELISA in which CQ
(50 μg/ml) was used as free antigen was also performed
to select hybridomas producing a monoclonal antibody
with a specific reactivity to CQ. The selected hybrido-
mas were cloned twice with the limited dilution method
and cultured on a large scale.
Purification of the monoclonal antibody
The produced monoclonal antibody was purified using a
Protein GFF column (0.46 × 11 cm; Pharmacia Biotech;
Uppsala, Sweden). The culture medium (700 ml) con-
taining the IgG was adjusted to pH 7 with 1 M Tris
solution and subjected to the column. The column was
washed with 10 mM phosphate buffer (pH 7). Adsorbed
IgG was eluted with 100 mM citrate buffer (pH 3). The
eluted IgG was neutralized with 1 M Tris solution and
then dialyzed against water five times. The isotype of
anti-CQ monoclonal antibody was classified by using a
mouse ID Kit (Cat no. 90-6550) from Zymed.
Preparation of standard reference solution and samples
used in the antibody-based competitive ELISA
Stock solutions and calibration standard
Stock solution of CQ was prepared in deionised water at
a concentration of 1 mg/ml. Working solutions were
prepared by appropriate dilution of the stock solution in
the ELISA dilution buffer (PBS + 0.37 M NaCl + 1%
BSA + 0.05% Tween 20, pH 7.2). These working solu-
tions were used to prepare seven calibration standards
in the range 0.1-2000 ng/ml. The standards were either
prepared in the dilution buffer for analysis of CQ tablets
or spiked in plasma for detecting CQ in plasma samples.
Competitive ELISA
For highly reliable results, checker board ELISA using
varying dilutions of the coating antigen (ADP-OA) and
anti-CQ HYB 317-02 was performed to determine the
optimal concentrations for the inhibition assay, at which
colour intensity was around 2.0. Afterwards competitive
inhibition assay was developed and validated. ADP: OA
(0.1 μg/ml) was used as coating antigen. One hundred
μl of the diluted antigen (1:400 in 0.05 M carbonate buf-
fer at pH 9.6) were added to each well and incubated
overnight at 4°C in moist boxes. After incubation the
plates were washed four times in washing buffer (PBS
with 0.5 M NaCl + 0.1% Triton-X100, pH 7.2). 100 μl of
each sample and CQ monoclonal antibodies (1:2500 in
the dilution buffer) were incubated for an hour at room
temperature and afterwards 100 μl were added to the
microtitre plates, final concentration of monoclonal
antibody in the samples was 1:5,000. Test plates were
incubated for 1 hour on a shaker at RT, and then
washed 4 times as before. 100 μl of HRP P0260
(1:1,000) were added to each well and the plates were
incubated for 1 hour at RT. Finally, the plates were
washed 4 times and 100 μl of the substrate-solution
(OPD 4 mg/ml in water and 0.4% hydrogen peroxide),
were added and the plates were incubated for 12 min-
utes and the reaction was stopped using 1.0 N H2SO4.
The colour intensity of the solution was read in a
microtitre reader at 490 nm wavelength.
Validation of the ELISA assay
Specificity of the developed monoclonal antibodies
Specificity and cross-reactivity was defined by the com-
petitive affinity of the monoclonal antibody for the
related 4-aminoquinolines and their metabolites; DCQ,
AQ and DAQ, hydroxyl-chloroquine, mefloquine, qui-
nine, pyrimethamine, trimethoprim, sulphadoxine and
sulphamethoxazole.
Linearity
Linearity of the ELISA method was tested over the
range 0.1 - 500 ng/ml.
Precision, accuracy and analytical recovery
The intra-run and inter-run variation from plate to plate
were tested using a high (300 ng/ml), a middle (150 ng/
ml) and a low level of CQ (75 ng/ml) from the calibra-
tion standards and run in triplicate in three plates under
the same conditions in the same day and over six days.
The coefficient of variation (%CV), accuracy and analyti-
cal recovery were then determined at each level.
Lower limit of detection (LLD) and limit of quantification
(LLQ)
LLD was defined as negative control ± 3 SD above the
mean OD for the 1:2 dilutions of plasma samples col-
lected from healthy Danish volunteers with no history of
CQ intake. The LLQ was determined by testing repli-
cates of low concentrations (25-0.1 ng/ml) of CQ spiked
in the dilution buffer or in plasma.
Applicability of the inhibition ELISA
Test of CQ concentration in tablets
The feasibility of the method was demonstrated by mea-
suring of CQ concentrations in pharmaceutical formula-
tions manufactured in Denmark (Malarex® and
Ercoquin®), Sudan (Eliquine®) and India (Chloroquine
from Vikram Laboratories). CQ content per each tested
tablet was 250 mg. The tested drugs were purchased
from pharmacies in quantities that contain 10 tablets.
Efforts were made to ensure that the drugs were not
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degraded by inadequate storage conditions, which would
have confounded the findings. The drugs were stored
for 4.5 months before the analysis at room temperature
and protected from sunlight and humidity. None of the
analysed drugs had expired upon analysis.
The amount of the active ingredient as declared by the
manufacturer was noted. Three samples were separately
analysed. In each run, three tablets of CQ were weighed
and finely pulverized. Then a proportion of this powder
corresponding to the average weight of a tablet were
accurately weighed and transferred to 100 ml volu-
metric-flask containing methanol: glacial acetic acid
(100:2%, respectively) for complete dissolution to
achieve a concentration of 2.5 mg/ml. This solution was
shaken vigorously and filtered. Three different concen-
trations (50, 100 and 200 ng/ml CQ) were made in the
ELISA dilution buffer and they were ran a long in inhi-
bition ELISA. Drug quality was assessed by comparing
the amount of active ingredient (CQ) in the eluents of
each dissolution sample against a known concentration
of standard CQ in the rage 0.1 - 500 ng/ml.
Test of CQ concentration in plasma samples
Plasma samples were donated by four volunteers, who
ingested a single dose of two tablets of Malarex
((Dumex Ltd, Copenhagen, Denmark) that contains 250
mg CQ base/tablet. The total amount of CQ given to
the volunteers was equivalent to 500 mg. Blood samples
were taken before drug intake, three hours thereafter
and at days 3, 7, 14, 21, and 28 post-treatment. The
samples were stored in dark at -20°C. Fifty μl of each
sample were tested by both high performance liquid
chromatography (HPLC) and the competitive ELISA to
validate the developed method. The values of CQ con-
centrations obtained by both methods were compared.
HPLC
A reverse phase HPLC with UV was used as the gold
standard for the developed ELISA. In the assay 50 μl
plasma samples diluted with 90 μl of water and alkali-
nised with 200 μl carbonate buffer (0.1 M, pH 9.5), were
extracted into 2 ml tert-butylmethylether. The drug was
thereafter re-extracted into an acidic aqueous phase
with 150 μl phosphate buffer (0.1 M, pH 4.0). The
HPLC column was a Zorbax SB-CN (5 mm, 4.6 ID ×
250 mm) protected by a LiChroCART® 4-4 LiChro-
spher® 100 CN (5 mm) guard column, and used with a
mobile phase consisted of acetonitril: phosphate buffer
(0.1 M, pH 2.3):sodium perchlorate (1.0 M); (13:86:1, v/
v). The flow rate was 1.2 ml/min. and the absorbance of
the drugs was measured at 237 nm.
Results
Hyper-immunization of BALB/c mice with ADP-OA-S3
yielded the monoclonal antibody HYB 317-02. The anti-
body was purified by G affinity chromatography in order
to develop a reliable ELISA to measure CQ in tablets
and in biological fluids. The isotype of anti-CQ HYB
317-02 was classified as having  light chain of the
IgG2b subclass antibody group. The optimal concentra-
tions of the antigen and anti CQ monoclonal antibody
concentrations to be used for the inhibition assay were
found to be 1:400 and 1:2500, respectively.
The standard curve
The full measuring range of the developed assay for CQ
extends from 0.1 to 500 ng/ml. Figure 2 shows a graph
that represents a typical calibration curve under the
optimal conditions used for the determination of specifi-
city, precision, accuracy and recovery.
Specificity, sensitivity and resolution
The monoclonal antibody was specific for CQ with no
cross-reactivity to the related aminoquinolines over a
concentration range of 10 - 500 ng/ml (Figure 3). The
monoclonal antibody does not cross-react with meflo-
quine, quinine, sulphadoxine, sulphamethoxazole, tri-
methoprim or pyrimethamine in the above mentioned
concentration range. The ELISA system was highly sen-
sitive with a LLD and LLQ of 0.1 and 3.9 ng/ml, respec-
tively. Endogenous materials in plasma or in CQ tablets
did not interfere. Within, between assay coefficients of
variation (CV) and analytical recovery are shown in
Table 1. To minimize variations due to evaporation of
the reagent, and uneven temperature during incubation
from day to day, a fresh standard curve was used with
each run. Both intra and inter-assay CV were < 10% at
all tested levels (Table 1).
Determination of CQ in tablets and in plasma
HPLC was used as a reference method in assessing the
ELISA technique. The accuracy of the method ranged
from 92 to 98 at all tested concentrations (10 - 2000
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Figure 2 Calibration curve for determination of chloroquine
concentration under the conditions used for estimation of
precision, recovery and accuracy.
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ng/ml) and the recovery of CQ in the therapeutical for-
mulations was found to range from 95-96% (Table 2).
The percentage of the active ingredient (CQ) in the four
formulations tested in this study was found to be
between 98-104%. Plasma concentrations of CQ deter-
mined by both ELISA and HPLC for the four volunteers
are shown in Figure 4. There was a good correlation (r
ranged from 0.96-0.99) and essentially identical results
were obtained by both analytical methods (Figure 5).
Discussion
CQ (Figure 1) is poorly immunogenic because of its
low molecular weight. For the production of a suffi-
cient amount of antibody against CQ, the hapten ADP
(Figure 1) was conjugated to ovalbumin (OA) and the
carrier protein S3. The hapten serves as an epitope for
binding to the antibodies on the B-cell surface and the
carrier protein provides class II T-cell receptor binding
sites necessary for T helper cell activation and
subsequently for antibody production. The hapten
which is an analogue to the N-side chain of CQ was
chosen for the production of a monoclonal that could
not cross-react with the other aminoquinoline drugs,
as illustrated in Figure 2. The hapten was easily linked
to the bi-functional linker glutaraldehyde that provides
covalent bonds to the amino groups in the hapten and
in the carrier protein. The bridge formed by glutaral-
dehyde could be recognized as an epitope by subse-
quent immunization.
Validation of the ELISA shows that the developed
technique could discriminate CQ from other anti-malar-
ial drugs, was easy-to-handle and a very sensitive tool
for the detection of CQ with a lower limit of detection
at 0.1 ng/ml. ELISA levels of CQ in tablets and in
plasma showed high agreement with the levels obtained
by HPLC (r = 0.98) and the specificity in the negative
control group was 100%. However, high plasma CQ
concentrations obtained in this study might be due to
the facts that Blood samples were separated immediately
after sample collection, plasma were kept at - 20°C in
tubes treated with chlorodimethylsilane in toluene (50/o,
v/v) in order to minimize drug adsorption and plasma
samples were analysed two days after the collection of
day 28 samples. Although the developed ELISA is as
sensitive as gold standard, the HPLC, further validation
in large field trial is needed.
The ELISA method has also the advantage of conveni-
ence and affordability as well as the ability to perform
analysis on large number of samples in remote environ-
ments, where conditions such as temperature, humidity
and reagent quality could be quite variable. It is impor-
tant to include reference positive standards and negative
control in each run to confirm the integrity of the assay.
The technique is field-friendly and only requires an
ELISA reader for quantitative measurements.
Other achievements with the present assay also
include commercially available monoclonal antibody,
simple extraction procedure of CQ from pharmaceutical
formulations using standard organic liquids and ELISA
buffers. With the developed ELISA, it took about 4 h to
run a maximum of 39 patients/tablets, including nine
standards and the internal controls. Only 50 μl plasma
test matrix is required for the analysis. Considering only
reagents, the cost of the ELISA system is roughly less
than US $2 per sample.
Figure 3 Cross-reactivity between chloroquine, desethyl
chloroquine, amodiaquine and desethyl amodiaquine in
plasma samples.
Table 1 Precision and analytical recovery of a high,
medium and low concentrations of CQ in plasma
Parameter Low
concentration
75 ng/ml
Medium
concentration
150 ng/ml
High
concentration
300 ng/ml
Within assay
CV%
6.5 6.9 5.7
Between assay
CV%
6.8 6.8 6.2
Analytical
recovery
92.2% 93.8% 93.4%
CV: Coefficient of variation.
Table 2 Precision and analytical recovery of CQ in
pharmaceutical formulations
Nominal concentration (ng/ml) Recovery (%) Precision (%RSD)
200 97,2 3.1
100 95.0 5
50 95.0 5.4
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Having these credits, the developed ELISA could be
used for selection of subjects for in vitro sensitivity tests,
where previous drug intake or/& drug pressure has to
be tested and for quality screening of pharmaceutical
formulations. Quality testing of CQ is done by sophisti-
cated and expensive analytical methods that require
expert personnel for both operation and maintenance.
These resources are, unfortunately, not always available
in the developing world, resulting in inadequate over-
sight of drug quality. As a consequence counterfeit and
poor quality drugs which is already a huge problem, will
continue to proliferate. Studies from Tanzania and
Cameroon have shown that more than 38% of the tested
CQ tablets had either no active ingredient, an insuffi-
cient active ingredient, the wrong ingredient, or
unknown ingredient(s) [6,21]. However, in the four CQ
brands, which were tested in this study the percentage
of the active ingredient (98 and 104%) met the European
Pharmacopoeia Content requirements of 95 - 105%.
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Figure 4 Chloroquine concentration measured by HPLC and the inhibition ELSA using CQ MAb HYB 317-02 in 4 volunteers after an
ingestion of a single dose of 500 mg CQ base.
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Figure 5 Chloroquine concentrations measured by HPLC and
the inhibition ELISA.
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Studies from Malawi and other countries have shown
the return of CQ susceptible malaria after the drug use
was abandoned [22]. This gives the possibility of using
CQ for malaria prevention in the future as CQ is safe,
well tolerated and has long elimination half-life. CQ
could also be used in combination with other drugs
with different pharmacokinetic (PK) and pharmacody-
namic (PD) profiles for treatment of malaria. The devel-
oped ELISA could be used to monitor CQ quality in
tablets and to identify the PK-PD profiles of CQ in trails
that will identify combinations that could deter the ree-
mergence of resistance [22].
Conclusion
An antibody-based ELISA has been developed for deter-
mination of CQ in anti-malarial tablets and in plasma.
The method is simple, fast, sensitive and accurate. The
results from validation indicate that the proposed
method can be applied for routine determination of CQ
in plasma samples and in pharmaceutical formulations.
Determination of CQ concentrations in tablets will
hopefully improve quality assurance of drugs, quality of
treatment and will minimize cross resistance between
CQ and the ACT partners currently in use. The metho-
dology has been exploited to develop monoclonal anti-
bodies for ACT drugs.
Acknowledgements
The authors are grateful to the late Jimmy Weng and Ulla Abildrup for the
good technical assistance and for Council for Development Research (RUF)/
Denmark for funding the project (project No. 91179).
Author details
1Centre for Medical Parasitology at Department of International Health,
Immunology and Microbiology, University of Copenhagen and Department
of Infectious Diseases, Copenhagen University Hospital, CSS Oster
Farimagsgade 5, 1014 Copenhagen K, Denmark. 2Bio Port A/S/. Grusbakken
8, DK-2820 Gentofte, Denmark. 3Department of Toxicology, Bispebjerg
Hospital, Bispebjerg Bakke 23 2400 Copenhagen NV, Denmark. 4Institute of
molecular medicine, Department of Cancer and Inflammation, University of
Southern Denmark, DK-5000 Odense.
Authors’ contributions
I K, MA, AR & IB design the study, CK supervised monoclonal antibody
development, CR & I K developed the antibody, IK & MA developed and
validated the CQ ELISA assay, LH did the HPLC work. IK wrote the
manuscript and all authors read and approved the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 6 February 2011 Accepted: 24 August 2011
Published: 24 August 2011
References
1. Teka H, Petros B, Yamuah L, Tesfaye G, Elhassan I, Muchohi S, Kokwaro G,
Aseffa A, Engers H: Chloroquine-resistant Plasmodium vivax malaria in
Debre Zeit, Ethiopia. Malar J 2008, 7:220.
2. Raghavendra K, Verma V, Srivastava HC, Gunasekaran K, Sreehari U, Dash AP:
Therapeutic responses of Plasmodium vivax and P. falciparum to
chloroquine, in an area of western India where P. vivax predominates.
Ann Trop Med Parasitol 2008, 102:47-480.
3. Naing Cho, Aung Kyan, Win Daw-Khin, Wah Mak Joon: Efficacy and safety
of Chloroquine in treatment of uncomplicated Plasmodium vivax in
endemic countries. Trans R Soc Trop Med Hyg 2010, 104:695-705.
4. Ikeoluwapo OAjayi, Edmund NBrowne, Garshong Bertha, Bateganya Fred,
Yusuf Bidemi, Agyei-Baffour Peter, Doamekpor Leticia, Balyeku Andrew,
Munguti Kaendi, Cousens Simon, Pagnoni Franco: Feasibility and
acceptability of artemisinin-based combination therapy for the home
management of malaria in four African sites. Malar J 2008, 7:6.
5. Barnadas C, Ratsimbasoa A, Tichit M, Bouchier C, Jahevitra M, Picot S,
Ménard D: Plasmodium vivax resistance in Madagascar: clinical efficacy
and polymorphisms of pvmdr1 and pvcrt-o genes. Antimicrob Agents
Chemother 2008, 52:12.
6. Onwujekwe O, Kaur H, Dike N, Shu E, Uzochukwu B, Hanson K, Okoye V,
Okonkwo P: Quality of anti-malarial drugs provided by public and
private healthcare providers in south-east Nigeria. Malar J 2009, 8:22.
7. Tipke Maike, Diallo Salou, Coulibaly Boubacar, Störzinger Dominic, Hoppe-
Tichy Torsten, Sie Ali, Müller Olaf: Substandard anti-malarial drugs in
Burkina Faso. Malar J 2008, 7:95.
8. Bate Roger, Coticelli Philip, Tren Richard, Attaran Amir: Antimalarial drug
quality in the most severely malarious parts of Africa - A six country
study. PloS One 2008, 3:e2132.
9. Basco LK: Molecular epidemiology of malaria in Cameroon. XIX. Quality
of antimalarial drugs used for self-medication. Am J Trop Med Hyg 2004,
70:245-250.
10. Dondorp AM, Newton PN, Mayxay M, Van Damme W, Smithuis FM: Fake
antimalarials in Southeast Asia are a major impediment to malaria
control: multinational cross-sectional survey on the prevalence of fake
antimalarials. Trop Med Int Health 2004, 9:1241-1246.
11. Adelusi SA, Salako LA: Improved fluorimetric assay of chloroquine in
biological samples. J Pharm Pharmacol 1980, 32:711-712.
12. Kazyak L, Knoblock E: Application of gas chromatography to analytical
toxicology. Anal Chem 1963, 35:1448-1452.
13. Bergquist Y: Sensitive methods for determining chloroquine and its
metabolites in human plasma and urine by HPLC. J Chromatogr 1980,
221:119-127.
14. Christian F: A radioimmunoassay for the antimalarial drug chloroquine.
Clin Chem 1986, 742-745.
15. Schwick P, Eggelte TA, Hess F, Tueumuna TT, Payne D, Nothdurft HD, von
Sonnenburg F, Löscher T: Sensitive ELISA dipstick test for the detection
of chloroquine in urine under field conditions. Trop Med Int Health 1998,
3:828-832.
16. Witte AM, Klever HJ, Brabin BJ, Eggelte TA, Vander Kaay HJ, Alpers MP: Field
evaluation of the use of an ELISA to detect chloroquine and its
metabolites in blood, urine and breast-milk. Trans R Soc Trop Med Hyg
1990, 84:521-525.
17. Shenton FC, Bots M, Menon A, Eggelte TA, de Wit M, Greenwood BM: An
ELISA test for detecting chloroquine in urine. Trans R Soc Trop Med Hyg
1988, 82:216-220.
18. Sai VV, Mahajan S, Contractor AQ, Mukherji S: Immobilization of antibodies
on polyaniline films and its application in a piezoelectric immunosensor.
Anal Chem 2006, 78:8368-8373.
19. Rowell V, Rowell FJ, Baker A, Laurie D, Sidki AM: A specific ELISA method
for determining chloroquine in urine or dried blood spots. Bull World
Health Organ 1988, 66:211-217.
20. Galfre G, Milstein C: Preparation of monoclonal antibodies: Strategies and
procedures. Methods Enzymol 1981, 73:3-46.
21. Basco KLeonardo: Molecular epidemiology of malaria in Cameroon: XIX.
Quality of antimalarial drugs used for self-medication. Am J Trop Med
Hyg 2004, 70:245-250.
22. Laufer MK, Takala-Harrison S, Dzinjalamala FK, Stine OC, Taylor TE, Plowe CV:
Return of chloroquine-susceptible falciparum malaria in Malawi was a
re-expansion of diverse susceptible parasites. J Infect Dis 2010, 1:801-808.
doi:10.1186/1475-2875-10-249
Cite this article as: Khalil et al.: Development of ELISA-based methods
to measure the anti-malarial drug chloroquine in plasma and in
pharmaceutical formulations. Malaria Journal 2011 10:249.
Khalil et al. Malaria Journal 2011, 10:249
http://www.malariajournal.com/content/10/1/249
Page 7 of 7
